PMC:7096775 / 4047-7331 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":2044,"end":2049},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":2044,"end":2049},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T29","span":{"begin":108,"end":116},"obj":"Disease"},{"id":"T30","span":{"begin":448,"end":456},"obj":"Disease"},{"id":"T31","span":{"begin":578,"end":590},"obj":"Disease"},{"id":"T32","span":{"begin":595,"end":603},"obj":"Disease"},{"id":"T33","span":{"begin":661,"end":669},"obj":"Disease"},{"id":"T34","span":{"begin":734,"end":771},"obj":"Disease"},{"id":"T35","span":{"begin":754,"end":771},"obj":"Disease"},{"id":"T36","span":{"begin":773,"end":777},"obj":"Disease"},{"id":"T37","span":{"begin":782,"end":795},"obj":"Disease"},{"id":"T39","span":{"begin":802,"end":810},"obj":"Disease"},{"id":"T40","span":{"begin":900,"end":909},"obj":"Disease"},{"id":"T41","span":{"begin":960,"end":968},"obj":"Disease"},{"id":"T42","span":{"begin":1025,"end":1033},"obj":"Disease"},{"id":"T43","span":{"begin":1640,"end":1652},"obj":"Disease"},{"id":"T44","span":{"begin":1742,"end":1750},"obj":"Disease"},{"id":"T45","span":{"begin":1817,"end":1821},"obj":"Disease"},{"id":"T46","span":{"begin":1891,"end":1897},"obj":"Disease"},{"id":"T47","span":{"begin":1959,"end":1972},"obj":"Disease"},{"id":"T49","span":{"begin":2044,"end":2057},"obj":"Disease"},{"id":"T50","span":{"begin":2132,"end":2136},"obj":"Disease"},{"id":"T51","span":{"begin":3087,"end":3091},"obj":"Disease"},{"id":"T52","span":{"begin":3093,"end":3128},"obj":"Disease"},{"id":"T53","span":{"begin":3099,"end":3128},"obj":"Disease"},{"id":"T54","span":{"begin":3130,"end":3134},"obj":"Disease"},{"id":"T55","span":{"begin":3136,"end":3173},"obj":"Disease"},{"id":"T56","span":{"begin":3156,"end":3173},"obj":"Disease"},{"id":"T57","span":{"begin":3175,"end":3183},"obj":"Disease"},{"id":"T58","span":{"begin":3265,"end":3274},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0002118"},{"id":"A38","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0005240"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0002118"},{"id":"A48","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0005240"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0005154"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0005002"},{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":174,"end":181},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T16","span":{"begin":286,"end":287},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T17","span":{"begin":332,"end":339},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T18","span":{"begin":1040,"end":1043},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T19","span":{"begin":1060,"end":1063},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T20","span":{"begin":1110,"end":1112},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T21","span":{"begin":1227,"end":1229},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T22","span":{"begin":1331,"end":1333},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T23","span":{"begin":1468,"end":1470},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T24","span":{"begin":1475,"end":1481},"obj":"http://purl.obolibrary.org/obo/UBERON_0003100"},{"id":"T25","span":{"begin":1494,"end":1496},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T26","span":{"begin":1501,"end":1503},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T27","span":{"begin":1506,"end":1508},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T28","span":{"begin":1535,"end":1537},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T29","span":{"begin":1779,"end":1781},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T30","span":{"begin":1841,"end":1843},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T31","span":{"begin":1850,"end":1852},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T32","span":{"begin":1853,"end":1855},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T33","span":{"begin":1989,"end":1991},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T34","span":{"begin":1997,"end":1999},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T35","span":{"begin":2044,"end":2049},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T36","span":{"begin":2044,"end":2049},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T37","span":{"begin":2073,"end":2076},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T38","span":{"begin":2082,"end":2085},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T39","span":{"begin":2111,"end":2116},"obj":"http://purl.obolibrary.org/obo/CLO_0001006"},{"id":"T40","span":{"begin":2248,"end":2250},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T41","span":{"begin":2275,"end":2277},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T42","span":{"begin":2316,"end":2321},"obj":"http://purl.obolibrary.org/obo/CLO_0001005"},{"id":"T43","span":{"begin":2328,"end":2330},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T44","span":{"begin":2331,"end":2333},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T45","span":{"begin":2359,"end":2361},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T46","span":{"begin":2377,"end":2381},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T47","span":{"begin":2377,"end":2381},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T48","span":{"begin":2701,"end":2706},"obj":"http://purl.obolibrary.org/obo/CLO_0053001"},{"id":"T49","span":{"begin":2708,"end":2713},"obj":"http://purl.obolibrary.org/obo/CLO_0001442"},{"id":"T50","span":{"begin":2883,"end":2885},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T51","span":{"begin":2888,"end":2890},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T52","span":{"begin":2997,"end":2999},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T2","span":{"begin":1261,"end":1263},"obj":"Chemical"},{"id":"T3","span":{"begin":1357,"end":1359},"obj":"Chemical"},{"id":"T4","span":{"begin":1361,"end":1363},"obj":"Chemical"},{"id":"T5","span":{"begin":1369,"end":1371},"obj":"Chemical"},{"id":"T6","span":{"begin":1374,"end":1376},"obj":"Chemical"},{"id":"T7","span":{"begin":1379,"end":1381},"obj":"Chemical"},{"id":"T8","span":{"begin":1384,"end":1386},"obj":"Chemical"},{"id":"T9","span":{"begin":1441,"end":1443},"obj":"Chemical"},{"id":"T10","span":{"begin":1450,"end":1452},"obj":"Chemical"},{"id":"T11","span":{"begin":1527,"end":1529},"obj":"Chemical"},{"id":"T12","span":{"begin":1615,"end":1617},"obj":"Chemical"},{"id":"T13","span":{"begin":1624,"end":1626},"obj":"Chemical"},{"id":"T14","span":{"begin":1637,"end":1639},"obj":"Chemical"},{"id":"T15","span":{"begin":1690,"end":1692},"obj":"Chemical"},{"id":"T16","span":{"begin":1699,"end":1701},"obj":"Chemical"},{"id":"T17","span":{"begin":1708,"end":1710},"obj":"Chemical"},{"id":"T18","span":{"begin":1796,"end":1798},"obj":"Chemical"},{"id":"T19","span":{"begin":1805,"end":1807},"obj":"Chemical"},{"id":"T20","span":{"begin":1859,"end":1861},"obj":"Chemical"},{"id":"T21","span":{"begin":1867,"end":1869},"obj":"Chemical"},{"id":"T22","span":{"begin":1875,"end":1877},"obj":"Chemical"},{"id":"T23","span":{"begin":1880,"end":1882},"obj":"Chemical"},{"id":"T24","span":{"begin":1888,"end":1890},"obj":"Chemical"},{"id":"T25","span":{"begin":1935,"end":1937},"obj":"Chemical"},{"id":"T26","span":{"begin":1943,"end":1945},"obj":"Chemical"},{"id":"T27","span":{"begin":1951,"end":1953},"obj":"Chemical"},{"id":"T28","span":{"begin":1956,"end":1958},"obj":"Chemical"},{"id":"T29","span":{"begin":2010,"end":2012},"obj":"Chemical"},{"id":"T30","span":{"begin":2018,"end":2020},"obj":"Chemical"},{"id":"T31","span":{"begin":2023,"end":2025},"obj":"Chemical"},{"id":"T32","span":{"begin":2028,"end":2030},"obj":"Chemical"},{"id":"T33","span":{"begin":2033,"end":2035},"obj":"Chemical"},{"id":"T34","span":{"begin":2041,"end":2043},"obj":"Chemical"},{"id":"T35","span":{"begin":2089,"end":2091},"obj":"Chemical"},{"id":"T36","span":{"begin":2097,"end":2099},"obj":"Chemical"},{"id":"T37","span":{"begin":2102,"end":2104},"obj":"Chemical"},{"id":"T38","span":{"begin":2107,"end":2109},"obj":"Chemical"},{"id":"T39","span":{"begin":2119,"end":2121},"obj":"Chemical"},{"id":"T40","span":{"begin":2176,"end":2178},"obj":"Chemical"},{"id":"T41","span":{"begin":2181,"end":2183},"obj":"Chemical"},{"id":"T42","span":{"begin":2186,"end":2188},"obj":"Chemical"},{"id":"T43","span":{"begin":2197,"end":2199},"obj":"Chemical"},{"id":"T44","span":{"begin":2262,"end":2264},"obj":"Chemical"},{"id":"T45","span":{"begin":2271,"end":2273},"obj":"Chemical"},{"id":"T46","span":{"begin":2283,"end":2285},"obj":"Chemical"},{"id":"T47","span":{"begin":2345,"end":2347},"obj":"Chemical"},{"id":"T48","span":{"begin":2350,"end":2352},"obj":"Chemical"},{"id":"T49","span":{"begin":2355,"end":2357},"obj":"Chemical"},{"id":"T50","span":{"begin":2377,"end":2381},"obj":"Chemical"},{"id":"T51","span":{"begin":2419,"end":2421},"obj":"Chemical"},{"id":"T52","span":{"begin":2428,"end":2430},"obj":"Chemical"},{"id":"T53","span":{"begin":2433,"end":2435},"obj":"Chemical"},{"id":"T54","span":{"begin":2438,"end":2440},"obj":"Chemical"},{"id":"T55","span":{"begin":2443,"end":2445},"obj":"Chemical"},{"id":"T56","span":{"begin":2448,"end":2450},"obj":"Chemical"},{"id":"T57","span":{"begin":2453,"end":2455},"obj":"Chemical"},{"id":"T58","span":{"begin":2518,"end":2520},"obj":"Chemical"},{"id":"T59","span":{"begin":2527,"end":2529},"obj":"Chemical"},{"id":"T60","span":{"begin":2532,"end":2534},"obj":"Chemical"},{"id":"T61","span":{"begin":2537,"end":2539},"obj":"Chemical"},{"id":"T62","span":{"begin":2542,"end":2544},"obj":"Chemical"},{"id":"T63","span":{"begin":2547,"end":2549},"obj":"Chemical"},{"id":"T64","span":{"begin":2552,"end":2554},"obj":"Chemical"},{"id":"T65","span":{"begin":2615,"end":2617},"obj":"Chemical"},{"id":"T66","span":{"begin":2624,"end":2626},"obj":"Chemical"},{"id":"T67","span":{"begin":2629,"end":2631},"obj":"Chemical"},{"id":"T68","span":{"begin":2634,"end":2636},"obj":"Chemical"},{"id":"T69","span":{"begin":2639,"end":2641},"obj":"Chemical"},{"id":"T70","span":{"begin":2644,"end":2646},"obj":"Chemical"},{"id":"T71","span":{"begin":2649,"end":2651},"obj":"Chemical"},{"id":"T72","span":{"begin":2794,"end":2796},"obj":"Chemical"},{"id":"T73","span":{"begin":2798,"end":2800},"obj":"Chemical"},{"id":"T74","span":{"begin":2809,"end":2811},"obj":"Chemical"},{"id":"T75","span":{"begin":2814,"end":2816},"obj":"Chemical"},{"id":"T76","span":{"begin":2819,"end":2821},"obj":"Chemical"},{"id":"T77","span":{"begin":2824,"end":2826},"obj":"Chemical"},{"id":"T78","span":{"begin":2829,"end":2831},"obj":"Chemical"},{"id":"T79","span":{"begin":2893,"end":2895},"obj":"Chemical"},{"id":"T80","span":{"begin":2902,"end":2904},"obj":"Chemical"},{"id":"T81","span":{"begin":2911,"end":2913},"obj":"Chemical"},{"id":"T82","span":{"begin":2916,"end":2918},"obj":"Chemical"},{"id":"T83","span":{"begin":2921,"end":2923},"obj":"Chemical"},{"id":"T84","span":{"begin":3002,"end":3004},"obj":"Chemical"},{"id":"T85","span":{"begin":3011,"end":3013},"obj":"Chemical"},{"id":"T86","span":{"begin":3020,"end":3022},"obj":"Chemical"},{"id":"T87","span":{"begin":3025,"end":3027},"obj":"Chemical"},{"id":"T88","span":{"begin":3030,"end":3032},"obj":"Chemical"},{"id":"T89","span":{"begin":3064,"end":3066},"obj":"Chemical"},{"id":"T90","span":{"begin":3232,"end":3234},"obj":"Chemical"}],"attributes":[{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_30780"},{"id":"A51","pred":"chebi_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A57","pred":"chebi_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A58","pred":"chebi_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A59","pred":"chebi_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A60","pred":"chebi_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A61","pred":"chebi_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A69","pred":"chebi_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A73","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A75","pred":"chebi_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A76","pred":"chebi_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A77","pred":"chebi_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A78","pred":"chebi_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T27","span":{"begin":0,"end":40},"obj":"Sentence"},{"id":"T28","span":{"begin":41,"end":155},"obj":"Sentence"},{"id":"T29","span":{"begin":156,"end":261},"obj":"Sentence"},{"id":"T30","span":{"begin":262,"end":383},"obj":"Sentence"},{"id":"T31","span":{"begin":384,"end":476},"obj":"Sentence"},{"id":"T32","span":{"begin":477,"end":577},"obj":"Sentence"},{"id":"T33","span":{"begin":578,"end":693},"obj":"Sentence"},{"id":"T34","span":{"begin":694,"end":835},"obj":"Sentence"},{"id":"T35","span":{"begin":836,"end":980},"obj":"Sentence"},{"id":"T36","span":{"begin":981,"end":1033},"obj":"Sentence"},{"id":"T37","span":{"begin":1034,"end":1144},"obj":"Sentence"},{"id":"T38","span":{"begin":1145,"end":1245},"obj":"Sentence"},{"id":"T39","span":{"begin":1246,"end":1299},"obj":"Sentence"},{"id":"T40","span":{"begin":1300,"end":1386},"obj":"Sentence"},{"id":"T41","span":{"begin":1387,"end":1474},"obj":"Sentence"},{"id":"T42","span":{"begin":1475,"end":1549},"obj":"Sentence"},{"id":"T43","span":{"begin":1550,"end":1639},"obj":"Sentence"},{"id":"T44","span":{"begin":1640,"end":1721},"obj":"Sentence"},{"id":"T45","span":{"begin":1722,"end":1816},"obj":"Sentence"},{"id":"T46","span":{"begin":1817,"end":1890},"obj":"Sentence"},{"id":"T47","span":{"begin":1891,"end":1958},"obj":"Sentence"},{"id":"T48","span":{"begin":1959,"end":2043},"obj":"Sentence"},{"id":"T49","span":{"begin":2044,"end":2121},"obj":"Sentence"},{"id":"T50","span":{"begin":2122,"end":2199},"obj":"Sentence"},{"id":"T51","span":{"begin":2200,"end":2285},"obj":"Sentence"},{"id":"T52","span":{"begin":2286,"end":2368},"obj":"Sentence"},{"id":"T53","span":{"begin":2369,"end":2455},"obj":"Sentence"},{"id":"T54","span":{"begin":2456,"end":2554},"obj":"Sentence"},{"id":"T55","span":{"begin":2555,"end":2651},"obj":"Sentence"},{"id":"T56","span":{"begin":2652,"end":2725},"obj":"Sentence"},{"id":"T57","span":{"begin":2726,"end":2831},"obj":"Sentence"},{"id":"T58","span":{"begin":2832,"end":2923},"obj":"Sentence"},{"id":"T59","span":{"begin":2924,"end":3032},"obj":"Sentence"},{"id":"T60","span":{"begin":3033,"end":3086},"obj":"Sentence"},{"id":"T61","span":{"begin":3087,"end":3284},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":578,"end":590},"obj":"Phenotype"},{"id":"T10","span":{"begin":734,"end":771},"obj":"Phenotype"},{"id":"T11","span":{"begin":773,"end":777},"obj":"Phenotype"},{"id":"T12","span":{"begin":900,"end":909},"obj":"Phenotype"},{"id":"T13","span":{"begin":1640,"end":1652},"obj":"Phenotype"},{"id":"T14","span":{"begin":1817,"end":1821},"obj":"Phenotype"},{"id":"T15","span":{"begin":1891,"end":1897},"obj":"Phenotype"},{"id":"T16","span":{"begin":2044,"end":2057},"obj":"Phenotype"},{"id":"T17","span":{"begin":3099,"end":3119},"obj":"Phenotype"},{"id":"T18","span":{"begin":3130,"end":3134},"obj":"Phenotype"},{"id":"T19","span":{"begin":3136,"end":3173},"obj":"Phenotype"},{"id":"T20","span":{"begin":3265,"end":3274},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0001392"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0006510"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"2_test","denotations":[{"id":"32186278-32112886-29336348","span":{"begin":1152,"end":1153},"obj":"32112886"},{"id":"32186278-32007143-29336349","span":{"begin":1174,"end":1175},"obj":"32007143"},{"id":"32186278-32075786-29336350","span":{"begin":1185,"end":1187},"obj":"32075786"},{"id":"32186278-32404696-29336351","span":{"begin":1213,"end":1214},"obj":"32404696"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"MyTest","denotations":[{"id":"32186278-32112886-29336348","span":{"begin":1152,"end":1153},"obj":"32112886"},{"id":"32186278-32007143-29336349","span":{"begin":1174,"end":1175},"obj":"32007143"},{"id":"32186278-32075786-29336350","span":{"begin":1185,"end":1187},"obj":"32075786"},{"id":"32186278-32404696-29336351","span":{"begin":1213,"end":1214},"obj":"32404696"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"81","span":{"begin":500,"end":508},"obj":"Species"},{"id":"82","span":{"begin":670,"end":678},"obj":"Species"},{"id":"83","span":{"begin":720,"end":728},"obj":"Species"},{"id":"84","span":{"begin":811,"end":819},"obj":"Species"},{"id":"85","span":{"begin":108,"end":116},"obj":"Disease"},{"id":"86","span":{"begin":448,"end":456},"obj":"Disease"},{"id":"87","span":{"begin":578,"end":590},"obj":"Disease"},{"id":"88","span":{"begin":595,"end":603},"obj":"Disease"},{"id":"89","span":{"begin":661,"end":669},"obj":"Disease"},{"id":"90","span":{"begin":734,"end":771},"obj":"Disease"},{"id":"91","span":{"begin":773,"end":777},"obj":"Disease"},{"id":"92","span":{"begin":782,"end":795},"obj":"Disease"},{"id":"93","span":{"begin":802,"end":810},"obj":"Disease"},{"id":"104","span":{"begin":1025,"end":1033},"obj":"Disease"},{"id":"105","span":{"begin":1554,"end":1569},"obj":"Disease"},{"id":"106","span":{"begin":1640,"end":1652},"obj":"Disease"},{"id":"107","span":{"begin":1742,"end":1750},"obj":"Disease"},{"id":"108","span":{"begin":1817,"end":1821},"obj":"Disease"},{"id":"109","span":{"begin":1891,"end":1897},"obj":"Disease"},{"id":"110","span":{"begin":1959,"end":1972},"obj":"Disease"},{"id":"111","span":{"begin":2044,"end":2057},"obj":"Disease"},{"id":"112","span":{"begin":2132,"end":2136},"obj":"Disease"},{"id":"113","span":{"begin":2945,"end":2960},"obj":"Disease"},{"id":"117","span":{"begin":910,"end":918},"obj":"Species"},{"id":"118","span":{"begin":900,"end":909},"obj":"Disease"},{"id":"119","span":{"begin":960,"end":968},"obj":"Disease"},{"id":"127","span":{"begin":3275,"end":3283},"obj":"Species"},{"id":"128","span":{"begin":3087,"end":3091},"obj":"Disease"},{"id":"129","span":{"begin":3093,"end":3128},"obj":"Disease"},{"id":"130","span":{"begin":3130,"end":3134},"obj":"Disease"},{"id":"131","span":{"begin":3136,"end":3173},"obj":"Disease"},{"id":"132","span":{"begin":3185,"end":3204},"obj":"Disease"},{"id":"133","span":{"begin":3265,"end":3274},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"tao:has_database_id","subj":"81","obj":"Tax:9606"},{"id":"A82","pred":"tao:has_database_id","subj":"82","obj":"Tax:9606"},{"id":"A83","pred":"tao:has_database_id","subj":"83","obj":"Tax:9606"},{"id":"A84","pred":"tao:has_database_id","subj":"84","obj":"Tax:9606"},{"id":"A85","pred":"tao:has_database_id","subj":"85","obj":"MESH:C000657245"},{"id":"A86","pred":"tao:has_database_id","subj":"86","obj":"MESH:C000657245"},{"id":"A87","pred":"tao:has_database_id","subj":"87","obj":"MESH:D006973"},{"id":"A88","pred":"tao:has_database_id","subj":"88","obj":"MESH:D003920"},{"id":"A89","pred":"tao:has_database_id","subj":"89","obj":"MESH:C000657245"},{"id":"A90","pred":"tao:has_database_id","subj":"90","obj":"MESH:D029424"},{"id":"A91","pred":"tao:has_database_id","subj":"91","obj":"MESH:D029424"},{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:D007674"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:C000657245"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"MESH:C000657245"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D002908"},{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"MESH:D006973"},{"id":"A107","pred":"tao:has_database_id","subj":"107","obj":"MESH:D003920"},{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"MESH:D029424"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"MESH:D009369"},{"id":"A110","pred":"tao:has_database_id","subj":"110","obj":"MESH:D007674"},{"id":"A111","pred":"tao:has_database_id","subj":"111","obj":"MESH:D008107"},{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"MESH:D012128"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"MESH:D002908"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Tax:9606"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"MESH:D011014"},{"id":"A119","pred":"tao:has_database_id","subj":"119","obj":"MESH:C000657245"},{"id":"A127","pred":"tao:has_database_id","subj":"127","obj":"Tax:9606"},{"id":"A128","pred":"tao:has_database_id","subj":"128","obj":"MESH:D012128"},{"id":"A129","pred":"tao:has_database_id","subj":"129","obj":"MESH:D012128"},{"id":"A130","pred":"tao:has_database_id","subj":"130","obj":"MESH:D029424"},{"id":"A131","pred":"tao:has_database_id","subj":"131","obj":"MESH:D029424"},{"id":"A132","pred":"tao:has_database_id","subj":"132","obj":"MESH:D018352"},{"id":"A133","pred":"tao:has_database_id","subj":"133","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Demographics, comorbidities and outcomes\nCrude and adjusted values of mean and median age were lower in all COVID-19 case series compared with SPP (Table). The proportion of females differed between the case series, ranging from 32% in Wuhan to 59% in Zhejiang. The adjusted SPP showed a range from 39% to 42% in the proportions of females throughout the 5 years under consideration. The overall proportion of comorbidities was much smaller in the COVID-19 case series (range: 20–51%) than in German patients, where the proportion ranged from 70% to 77%, depending on the year. Hypertension and diabetes were the most important chronic comorbidities both among COVID-19 patients and among SPP. However, there were fewer patients with chronic obstructive pulmonary disease (COPD) or renal disease among COVID-19 patients than among SPP.\nTable Epidemiological and clinical characteristics of sentinel pneumonia patients, crude and adjusted for age and sex, and COVID-19 case series\nCharacteristics SPP, crude SPP, adjusted COVID-19\nWeeks 3–5, 2015–19 Weeks 3–5, 2015–19 20 days 28 days 31 days 26 days 22 days 30 days 17 days 23 days\nWuhan [5] Wuhan [6] Wuhan [7] Hubei [10] Beijing [8] Shenzhen [9] Zhejiang [11] Zhejiang [12]\nNumber 5,829 NA 99 138 82 137 262 298 62 91\nMean age in years (range) 73 (71–75) 63 (61–66) 55.5 NA NA 55 NA NA NA NA\nMedian age in years (range) 77 (76–78) 67 (65–69) NA 56 NA 57 47.5 47 41 50\nFemale, % (range) 45 (44–45) 41 (39–42) 32 46 NA 56 52 50 44 59\nAny chronic disease, % (range) 82 (80–85) 74 (70–77) 51 46 NA 20 NA 32 32 NA\nHypertension, % (range) 58 (56–62) 49 (46–53) NA 31 NA 10 NA 13 8 16\nEndocrine condition/diabetes, % (range) 28 (26–30) 24 (22–26) 13 14 NA 10 NA 6 2 9\nCOPD, % (range) 20 (19–22) 20 (18–22) NA 3 NA 2 NA NA 2 NA\nCancer, % (range) 7 (6–8) 8 (7–9) 1 7 NA 2 NA 1 NA NA\nRenal disease, % (range) 37 (34–40) 27 (24–29) NA 3 NA NA NA NA 2 NA\nLiver disease, % (range) 4 (3–4) 5 (3–6) NA 3 NA NA NA 3 11 NA\nOf total: ARDS, % (range) 1 (0–1) 1 (0–1) 17 20 NA NA NA 4 2 NA\nOf total: ventilated, % (range) 8 (7–10) 9 (8–11) 20 23 NA 25 NA 11 2 NA\nOf total: ICU, % (range) 19 (18–21) 20 (18–22) 23 26 NA NA NA 11 2 10\nOf ICU: male, % (range) 58 (55–60) 61 (56–66) NA 61 NA NA NA NA NA NA\nOf ICU: median age in years (range) 76 (74–78) 67 (64–68) NA 66 NA NA NA NA NA NA\nOf ICU: without chronic, % (range) 10 (7–12) 16 (10–19) NA 28 NA NA NA NA NA NA\nOf total: deceased, % (range) 9 (8–9) 6 (5–6) 11 4 6 12 1 0 0 0\nOf deceased: median age, in years (range) 83 (82–84) 78 (76–79) NA NA 72.5 NA NA NA NA NA\nOf deceased: \u003c 60 years, % (range) 5 (2–9) 13 (7–22) 36 NA 20 NA 30 NA NA NA\nOf deceased: without chronic disease, % (range) 13 (13–15) 13 (12–14) 18 NA 23 NA 30 NA NA NA\nStill hospitalised, % 58 62 NA 56 82 77 98 66\nARDS: acute respiratory distress syndrome; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease; ICU: intensive care unit; NA: not available; SPP: sentinel pneumonia patients."}